Prostate Cancer Prevalence in Men Over 75
Approximately 45-50% of men older than 75 years have prostate cancer detected at autopsy, though the vast majority of these cases are clinically insignificant and would never have caused symptoms or death during their lifetime.
Evidence from Autopsy Studies
The most direct answer comes from autopsy research examining men who died of causes unrelated to prostate cancer:
- In men aged 70 years and older, prostate cancer was found in 45% of autopsy specimens 1
- In men aged 90 years and older, the prevalence exceeds 50% 2
- A comprehensive literature review of over 29,000 autopsies found that prostate cancer prevalence increases progressively with age, reaching >50% in men ≥90 years 2
Critical Context: Clinical Significance
While the prevalence is high, the clinical implications are limited:
- Most autopsy-detected cancers are small (~0.5 cubic cm), low-grade, and organ-confined 2
- Only about 10% of autopsy-detected cases show extra-prostatic extension 2
- The prevalence of autopsy-detected prostate cancer is 30-fold greater than prostate cancer-specific mortality in each age category 2
Age-Related Mortality Patterns
The NCCN guidelines provide important mortality context:
- 70% of prostate cancer deaths occur after age 75 years 3
- However, these deaths typically occur after a period of metastatic disease, not from incidentally detected cancers 3
- A large proportion of men older than 70 years harbor cancer that would be unlikely to affect their life expectancy 4
Screening Implications
This high prevalence of clinically insignificant disease is precisely why:
- Very few men above age 75 years benefit from PSA screening 4, 5
- The USPSTF recommends against screening in men ≥75 years due to substantial overdetection risk 6, 7
- NCCN guidelines support screening only in very select patients >75 years (Category 2B recommendation) 4
Bottom Line
While roughly half of men over 75 have histologic prostate cancer, this represents predominantly indolent disease that poses minimal threat to survival or quality of life, explaining why screening is not recommended in this age group.